Pharming Group N.V. ADR (PHAR)

$PHAR I told you everything will be alright

$PHAR Investor Day PR. Huge revenue increase expected compared to street estimates. https://finance.yahoo.com/news/pharming-group-announces-2026-financial-060000234.html

$PHAR Gapping up. Guides to $415M revenue at midpoint for 2026. Estimates were $350M

$PHAR https://www.merlintrader.com/phar-pharming-group-adr-crl/

$PHAR thin biotech name under the radar needs volume

Looking for bounce $HOOD $EGO $VSEC $PHAR

$PHAR Kans om goedkoop in te slaan cq bijkopen

$PHAR (-16.8% pre) Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS https://ooc.bz/l/91586

$PHAR receives FDA Complete Response Letter for Joenja (leniolisib) in children aged 4-11 with APDS. Additional data needed on dosing and testing methods. https://notreload.xyz/fda-requests-more-data-for-joenja-in-younger-children-with-apds/

$PHAR What to watch for now: 1️⃣ Investor Day (Tomorrow, Feb 3): Management will host a virtual event to provide 2026 financial guidance and specific clarity on the CRL path forward. This is the primary catalyst for a sentiment reversal. 2️⃣ Type A Meeting: Pharming is requesting an urgent "Type A" meeting with the FDA to align on the resubmission timeline. These meetings typically occur within 30 days of the request. 3️⃣ Business as Usual: The existing approval for patients 12+ remains unaffected and continues to show strong growth (+35% YoY). With 2025 revenues hitting $376M and beating guidance, the company remains cash-flow positive and financially stable.

Pharming Stock Draws Retail Buzz After FDA Seeks More Data For Pediatric Immune Drug — Why Investors Aren’t Panicking $PHAR https://stocktwits.com/news/equity/markets/pharming-stock-draws-retail-buzz-after-fda-seeks-more-data-for-pediatric-immune-drug/cZbg0fRR4jU

$PHAR AMSTERDAM IS ALREADY BOUNCING OFF THE LOWS 📉➡️📈 European market opened in panic (-19%) but buyers are stepping in aggressively. We are now recovering to -14% and climbing. Why the reversal? Investors are finally reading the actual CRL text instead of just the headline. It's a dosing issue (PK) - NOT a safety failure. Revenue is safe - The 12+ adult market is unaffected. Fixable - Math and paperwork, not a broken drug. 🇺🇸 US Pre-market: Take note. Don't repeat the initial European knee-jerk reaction. The "Smart Money" is already buying the dip across the pond.

$PHAR Watching the Euronext price action right now (€1.385, down ~19%), and it’s a classic massive overreaction to a headline. If you actually read the CRL details, this is a "Soft Rejection": Underexposure (Not Toxicity!): The FDA isn't saying the drug is unsafe. They are worried low-weight kids aren't getting ENOUGH of it. This is a dosing/PK math problem to solve, not a safety failure. CMC / Batch Testing: This is a bureaucratic dispute over analytical methods in the lab. The factory isn't broken, the drug isn't contaminated. It's paperwork. The Reality: Safety: Clean. No serious adverse events. Revenue: Joenja is ALREADY approved for 12+. The cash cow is safe and unaffected by this. The market is pricing this like a total failure. It’s just a delay for the younger cohort. Let the weak hands in Europe fold—this dip is irrational based on the filings.

$PHAR such a stupid CRL!!!! READ THE FINE PRINT BEFORE YOU PANIC SELL This is the definition of a "Soft CRL". The market is reacting like the drug is toxic, but the FDA letter says the opposite: "Underexposure": The FDA is worried low-weight kids aren't getting enough of the drug. This is a DOSING adjustment (math problem), NOT a safety/toxicity issue. CMC: Issues with "analytical methods". This is a bureaucratic/testing fix, not a broken factory or contaminated product. Reality Check: Joenja is ALREADY approved & generating revenue for 12+ patients. The cash cow is fine. This is just a delay for the younger cohort expansion. Let the weak hands fold. This is a buyable dip for anyone who actually reads the filings.I am staying. Lets see how the Dutch ticker reacts...

$PHAR Totally bizarre CRL. fda worried that the tiniest children are not getting ENOUGH of the drug. So all getting sicker is better? So they gun it down for all. Not so smart. Unbelievable.

$F $ORCL $PHAR $CG $BCSF Top five weekend stock stories: 1) Ford (F) held discussions with Xiaomi (XIACF) over a partnership to help Chinese carmakers gain a foothold in the U.S., Demetri Sevastopulo, Christian Davies, Kana Inagaki, and Gloria Li of The Financial Times reports, citing four people familiar with the matter. During preliminary discussions, Ford explored forming a joint venture with Xiaomi to create EVs in the U.S., the sources added. Ford has also discussed with BYD (BYDDF) about a potential U.S. collaboration. 2) Oracle (ORCL) announced its full calendar year 2026 plan to fund the expansion of its Oracle Cloud Infrastructure business. Oracle is raising money in order to build additional capacity to meet the contracted demand from its largest Oracle Cloud Infrastructure customers. Oracle expects to raise $45 to $50 billion of gross cash proceeds during the 2026 calendar year. The company plans to achieve its funding objective by using a balanced combination of debt and equity financing to maintain a solid investment-grade balance sheet. 3) Pharming (PHAR) announced that the U.S. Food and Drug Administration, FDA, has issued a Complete Response Letter, CRL, to its supplemental New Drug Application, sNDA, for Joenja, an oral, selective phosphoinositide 3-kinase delta inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome, APDS, a rare primary immunodeficiency. The FDA raised an issue with the potential for underexposure in lower weight pediatric patients. As a result, the FDA has requested additional pediatric pharmacokinetic data to reassess the proposed pediatric doses and confirm that children in the lower weight dose groups can achieve exposure levels comparable to the approved adult and adolescent regimen. The letter also identified an issue with one of the analytical methods used for production batch testing, and the FDA requested additional data and clarification on this point. 4) Carlyle (CG) has started exploratory talks with UAE investors to bring in partners should its agreement to purchase Lukoil's international assets proceed, Shadia Nasralla and Anna Hirtenstein of Reuters reports, citing three sources with knowledge of the process. 5) Bain Capital (BCSF) has finalized plans to acquire FineToday in a deal set to be worth $1.29B, Reuters reports, citing Nikkei. CVC Capital Partners intends to divest all of FineToday's shares.

$PHAR was this really announced on a Sunday??? $AQST tom news either way

$PHAR $AQST

$PHAR Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS "The FDA raised an issue with the potential for underexposure in lower weight pediatric patients. As a result, the FDA has requested additional pediatric pharmacokinetic data to reassess the proposed pediatric doses and confirm that children in the lower weight dose groups can achieve exposure levels comparable to the approved adult and adolescent regimen."

$PHAR will buy the dip. Hopefully it’s a large drop